MorphoSys AG (WBO:MOR) Days Sales Outstanding : 49.57 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Days Sales Outstanding?

MorphoSys AG's average Accounts Receivable for the three months ended in Dec. 2023 was €32.1 Mil. MorphoSys AG's Revenue for the three months ended in Dec. 2023 was €59.1 Mil. Hence, MorphoSys AG's Days Sales Outstanding for the three months ended in Dec. 2023 was 49.57.

The historical rank and industry rank for MorphoSys AG's Days Sales Outstanding or its related term are showing as below:

WBO:MOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.41 Med: 77.76 Max: 161.83
Current: 98.58

During the past 13 years, MorphoSys AG's highest Days Sales Outstanding was 161.83. The lowest was 45.41. And the median was 77.76.

WBO:MOR's Days Sales Outstanding is ranked worse than
65.43% of 891 companies
in the Biotechnology industry
Industry Median: 71.97 vs WBO:MOR: 98.58

MorphoSys AG's Days Sales Outstanding declined from Dec. 2022 (101.94) to Dec. 2023 (49.57).

MorphoSys AG Days Sales Outstanding Historical Data

The historical data trend for MorphoSys AG's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Days Sales Outstanding Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

83.46

54.82

161.83

109.62

94.46

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															101.94	112.86	115.16	101.93	49.57

Competitive Comparison of MorphoSys AG's Days Sales Outstanding

For the Biotechnology subindustry, MorphoSys AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Days Sales Outstanding falls into.

MorphoSys AG Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

MorphoSys AG's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (91.231	+	32.094)	/	2 )	/	238.278	*	365
=	61.6625					/	238.278	*	365
=	94.46

MorphoSys AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	32.094)	/	1 )	/	59.078	*	365 / 4
=	32.094					/	59.078	*	365 / 4
=	49.57

MorphoSys AG (WBO:MOR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

MorphoSys AG Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.